AR091866A1 - Analogos del glucagon - Google Patents
Analogos del glucagonInfo
- Publication number
- AR091866A1 AR091866A1 ARP130102607A ARP130102607A AR091866A1 AR 091866 A1 AR091866 A1 AR 091866A1 AR P130102607 A ARP130102607 A AR P130102607A AR P130102607 A ARP130102607 A AR P130102607A AR 091866 A1 AR091866 A1 AR 091866A1
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- glu
- lys
- pharmaceutically acceptable
- gln
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 241000024188 Andala Species 0.000 abstract 3
- 208000013016 Hypoglycemia Diseases 0.000 abstract 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 1
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000005374 Poisoning Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 206010022498 insulinoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000021255 pancreatic insulinoma Diseases 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261674706P | 2012-07-23 | 2012-07-23 | |
| US201361785611P | 2013-03-14 | 2013-03-14 | |
| DKPA201300360 | 2013-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091866A1 true AR091866A1 (es) | 2015-03-04 |
Family
ID=49996630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102607A AR091866A1 (es) | 2012-07-23 | 2013-07-23 | Analogos del glucagon |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10442847B2 (forum.php) |
| EP (1) | EP2875043B1 (forum.php) |
| JP (3) | JP6534927B2 (forum.php) |
| KR (1) | KR102129235B1 (forum.php) |
| CN (2) | CN104662038B (forum.php) |
| AR (1) | AR091866A1 (forum.php) |
| AU (1) | AU2013295035B2 (forum.php) |
| BR (1) | BR112015001451B1 (forum.php) |
| CA (1) | CA2878991C (forum.php) |
| DK (1) | DK2875043T3 (forum.php) |
| EA (1) | EA033399B1 (forum.php) |
| ES (1) | ES2620111T3 (forum.php) |
| FI (1) | FIC20240034I1 (forum.php) |
| FR (1) | FR24C1043I1 (forum.php) |
| IL (1) | IL236554B (forum.php) |
| IN (1) | IN2015DN00544A (forum.php) |
| MX (1) | MX356957B (forum.php) |
| MY (1) | MY170671A (forum.php) |
| NL (1) | NL301294I2 (forum.php) |
| NZ (1) | NZ704043A (forum.php) |
| PH (1) | PH12015500115A1 (forum.php) |
| PL (1) | PL2875043T3 (forum.php) |
| SG (1) | SG11201500375PA (forum.php) |
| TW (1) | TWI642682B (forum.php) |
| UA (1) | UA117103C2 (forum.php) |
| WO (1) | WO2014016300A1 (forum.php) |
| ZA (1) | ZA201702364B (forum.php) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20121130A1 (es) | 2009-07-13 | 2012-08-30 | Zealand Pharma As | Analogos de glucagon acilados |
| CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
| AU2013295035B2 (en) | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| AU2014336098B2 (en) | 2013-10-17 | 2018-05-10 | Boehringer Ingelheim International Gmbh | Acylated glucagon analogues |
| WO2015067716A1 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| KR102310389B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐアゴニスト化合物及び方法 |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| KR102754148B1 (ko) | 2017-06-16 | 2025-01-15 | 질랜드 파마 에이/에스 | 글루카곤-유사-펩티드-2 (glp-2) 유사체의 투여를 위한 용량요법 |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
| BR112020000447A2 (pt) | 2017-07-14 | 2020-07-21 | Xeris Pharmaceuticals, Inc. | métodos de tratamento de hiperinsulinismo congênito |
| MX2020007768A (es) * | 2018-01-23 | 2020-11-12 | Xeris Pharmaceuticals Inc | Tratamiento contra hipoglucemia posbariátrica usando pequeñas dosis de glucagón estable. |
| WO2021185821A1 (en) | 2020-03-16 | 2021-09-23 | Zealand Pharma A/S | Liquid formulations of glucagon analogues |
| EP4357358A4 (en) * | 2021-06-18 | 2024-11-06 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | GLUCAGONE ANALOGUE AND MEDICAL USE THEREOF |
| CN113501871B (zh) * | 2021-07-21 | 2022-10-28 | 汉肽生物医药集团有限公司 | 一种固液相结合制备达西高血糖素的方法 |
| WO2025056677A1 (en) | 2023-09-15 | 2025-03-20 | Zealand Pharma A/S | Dasiglucagon for use in the treatment of congenital hyperinsulinism |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4288627A (en) | 1980-02-12 | 1981-09-08 | Phillips Petroleum Company | Oxidation of thiols employing cobalt molybdate/triethylamine catalyst |
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
| AU639570B2 (en) | 1990-05-09 | 1993-07-29 | Novozymes A/S | A cellulase preparation comprising an endoglucanase enzyme |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| WO1995005848A1 (en) | 1993-08-24 | 1995-03-02 | Novo Nordisk A/S | Protracted glp-1 |
| WO1995007098A1 (en) | 1993-09-07 | 1995-03-16 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5523449A (en) | 1995-05-17 | 1996-06-04 | Bayer Corporation | Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur |
| DE59712555D1 (de) | 1996-06-05 | 2006-04-06 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| US6858576B1 (en) | 1996-08-08 | 2005-02-22 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6384016B1 (en) | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| CN1271086C (zh) | 1996-08-30 | 2006-08-23 | 诺沃挪第克公司 | Glp－1衍生物 |
| IL128828A0 (en) | 1996-09-09 | 2000-01-31 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxy acid linker |
| DE69732640T2 (de) | 1996-09-09 | 2006-01-12 | Zealand Pharma A/S | Festphasen-peptidsynthese |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998022577A1 (en) | 1996-11-15 | 1998-05-28 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
| EP1629849B2 (en) | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6136784A (en) | 1997-01-08 | 2000-10-24 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
| WO1998035033A1 (en) | 1997-02-05 | 1998-08-13 | 1149336 Ontario Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
| AU7652998A (en) | 1997-05-07 | 1998-11-27 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | New cysteine derivatives, processes for their production, and pharmaceuticals containing them |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| DE69838791T3 (de) | 1997-08-08 | 2011-06-22 | Amylin Pharmaceuticals, Inc., Calif. | Neue exendinagonist verbindungen |
| MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| NZ504256A (en) | 1997-11-14 | 2003-01-31 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for treating diabetes |
| US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| EP1049486A4 (en) | 1997-12-05 | 2006-01-04 | Lilly Co Eli | GLP-1 FORMULATIONS |
| US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| CA2320371C (en) | 1998-02-13 | 2012-01-17 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| EP1950223A3 (en) | 1998-03-09 | 2009-05-13 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| WO1999049788A1 (en) | 1998-03-30 | 1999-10-07 | Focus Surgery, Inc. | Ablation system |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| ES2335066T3 (es) | 1998-08-10 | 2010-03-18 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas. |
| WO2000020592A1 (en) | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| KR100511855B1 (ko) | 1998-12-07 | 2005-09-02 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | Ｇｌｐ-1의 유사체 |
| DE60032331T2 (de) | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| KR100675711B1 (ko) | 1999-01-14 | 2007-02-01 | 아밀린 파마슈티칼스, 인크. | 신규 엑센딘 아고니스트 제제 및 이의 투여 방법 |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| DE60040333D1 (de) | 1999-03-17 | 2008-11-06 | Novo Nordisk As | Verfahren zur acylierung von peptiden und proteinen |
| US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
| US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| EP1175443A1 (en) | 1999-04-30 | 2002-01-30 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| PT1180121E (pt) | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| EP1330261B1 (en) | 2000-10-20 | 2010-06-09 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| KR20040070237A (ko) | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
| AU2003243929B2 (en) | 2002-07-04 | 2009-06-04 | Zp Holding Spv K/S | GLP-1 and methods for treating diabetes |
| EP1546200A2 (en) | 2002-10-02 | 2005-06-29 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
| EP1633390B1 (en) * | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| US7623530B2 (en) | 2003-11-20 | 2009-11-24 | Nokia Corporation | Indication of service flow termination by network control to policy decision function |
| RU2006131046A (ru) | 2004-01-30 | 2008-03-10 | Уэрейта Фармасьютикалз, Инк. (Ca) | Совместное применение агониста glp-1 и соединений гастрина |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| BRPI0517341A (pt) | 2004-11-12 | 2008-10-07 | Novo Nordisk As | composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2607566A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| JP2008543816A (ja) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| WO2007056362A2 (en) * | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007095737A1 (en) | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
| AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| CN101622276B (zh) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| EP2074140B8 (en) | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| CA2669806C (en) | 2006-11-08 | 2018-10-02 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| WO2008071010A1 (en) | 2006-12-12 | 2008-06-19 | Waratah Pharmaceuticals Inc. | Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CA2674354A1 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| WO2008101017A2 (en) | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| FR2917552B1 (fr) | 2007-06-15 | 2009-08-28 | Sagem Defense Securite | Procede de regulation de la gigue de transmission au sein d'un terminal de reception |
| EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| GB2455553B (en) | 2007-12-14 | 2012-10-24 | Nuaire Ltd | Motor mounting assembly for an axial fan |
| KR20100111683A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| BRPI0907371A2 (pt) | 2008-01-09 | 2015-11-24 | Sanofi Aventis Deutschland | derivados de insulina com um perfil de tempo-ação muito retardado |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| JP2011521621A (ja) | 2008-04-22 | 2011-07-28 | ケイス、ウエスタン、リザーブ、ユニバーシティ | アイソフォーム特異的インスリン類似体 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| CN103641907A (zh) | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
| CN104945500B (zh) | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| JP5753779B2 (ja) * | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| MY158627A (en) | 2008-07-31 | 2016-10-31 | Univ Case Western Reserve | Halogen-stabilized insulin |
| CN102171244B (zh) | 2008-08-07 | 2015-05-13 | 益普生制药股份有限公司 | 糖依赖性胰岛素释放肽的类似物 |
| JP5591243B2 (ja) | 2008-09-12 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ペプチド又はタンパク質のアシル化の方法 |
| MX2011006313A (es) | 2008-12-15 | 2011-09-27 | Zealand Pharma As | Analogos de glucagon. |
| BRPI0823377A2 (pt) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
| AU2008365556A1 (en) * | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| MX2011006320A (es) * | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US20100240883A1 (en) | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| EP2427493A1 (en) | 2009-05-08 | 2012-03-14 | F. Hoffmann-La Roche AG | Humanized anti-egfl7 antibodies and methods using same |
| IN2012DN00377A (forum.php) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
| PE20121130A1 (es) | 2009-07-13 | 2012-08-30 | Zealand Pharma As | Analogos de glucagon acilados |
| CA2784757A1 (en) | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| WO2011084808A2 (en) | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| CN102892425A (zh) | 2010-01-20 | 2013-01-23 | 西兰制药公司 | 心脏病症的治疗 |
| CA2788304A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| CN102933598A (zh) * | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011117416A1 (en) * | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| TWI523659B (zh) | 2010-04-27 | 2016-03-01 | 西蘭製藥公司 | 肽結合物 |
| CA2797431C (en) | 2010-04-27 | 2016-06-21 | Zhejiang Beta Pharma Inc. | Glucagon-like peptide-1 analogue and use thereof |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AP2013006671A0 (en) | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
| WO2011163473A1 (en) * | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| EP2637698B1 (en) | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| KR20140020292A (ko) | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
| CN106117343B (zh) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| EP2707713A2 (en) | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| CN103764673A (zh) | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
| MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| WO2013098408A1 (en) * | 2011-12-30 | 2013-07-04 | Zealand Pharma A/S | Glucagon and cck receptor agonist peptide conjugates |
| CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
| EA028929B1 (ru) | 2012-05-03 | 2018-01-31 | Зилэнд Фарма А/С | Аналоги глюкагоноподобного пептида-2 (glp-2) |
| AU2013295035B2 (en) | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| AU2014336098B2 (en) | 2013-10-17 | 2018-05-10 | Boehringer Ingelheim International Gmbh | Acylated glucagon analogues |
| KR102310389B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법 |
| AU2015220909A1 (en) | 2014-02-18 | 2016-07-14 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
-
2013
- 2013-07-23 AU AU2013295035A patent/AU2013295035B2/en active Active
- 2013-07-23 SG SG11201500375PA patent/SG11201500375PA/en unknown
- 2013-07-23 PL PL13756832T patent/PL2875043T3/pl unknown
- 2013-07-23 EA EA201590058A patent/EA033399B1/ru unknown
- 2013-07-23 WO PCT/EP2013/065519 patent/WO2014016300A1/en active Application Filing
- 2013-07-23 IN IN544DEN2015 patent/IN2015DN00544A/en unknown
- 2013-07-23 ES ES13756832.5T patent/ES2620111T3/es active Active
- 2013-07-23 KR KR1020157004545A patent/KR102129235B1/ko active Active
- 2013-07-23 CN CN201380038909.XA patent/CN104662038B/zh active Active
- 2013-07-23 MY MYPI2015000156A patent/MY170671A/en unknown
- 2013-07-23 NZ NZ704043A patent/NZ704043A/en unknown
- 2013-07-23 BR BR112015001451-8A patent/BR112015001451B1/pt active IP Right Grant
- 2013-07-23 UA UAA201500436A patent/UA117103C2/uk unknown
- 2013-07-23 DK DK13756832.5T patent/DK2875043T3/en active
- 2013-07-23 MX MX2015000990A patent/MX356957B/es active IP Right Grant
- 2013-07-23 AR ARP130102607A patent/AR091866A1/es active IP Right Grant
- 2013-07-23 JP JP2015523532A patent/JP6534927B2/ja active Active
- 2013-07-23 EP EP13756832.5A patent/EP2875043B1/en active Active
- 2013-07-23 CN CN201811143957.6A patent/CN109456400A/zh active Pending
- 2013-07-23 CA CA2878991A patent/CA2878991C/en active Active
- 2013-07-23 TW TW102126353A patent/TWI642682B/zh active
- 2013-07-23 US US14/417,074 patent/US10442847B2/en active Active
-
2015
- 2015-01-01 IL IL236554A patent/IL236554B/en active IP Right Grant
- 2015-01-20 PH PH12015500115A patent/PH12015500115A1/en unknown
-
2017
- 2017-04-04 ZA ZA2017/02364A patent/ZA201702364B/en unknown
-
2019
- 2019-05-23 JP JP2019096726A patent/JP2019187419A/ja active Pending
- 2019-09-11 US US16/566,992 patent/US11795204B2/en active Active
-
2021
- 2021-09-09 JP JP2021147080A patent/JP2022023029A/ja active Pending
-
2023
- 2023-09-21 US US18/371,057 patent/US20240067696A1/en active Pending
-
2024
- 2024-10-23 FI FIC20240034C patent/FIC20240034I1/fi unknown
- 2024-10-29 NL NL301294C patent/NL301294I2/nl unknown
- 2024-11-04 FR FR24C1043C patent/FR24C1043I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091866A1 (es) | Analogos del glucagon | |
| AR094178A1 (es) | Derivados de exendina-4 funcionalizada | |
| AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
| PE20142113A1 (es) | Analogos de glucagon | |
| AR098740A1 (es) | Análogos del péptido exendina-4 | |
| AR104932A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| AR090937A1 (es) | Compuestos agonista duales de gip-glp-1 y metodos para usarlos | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| AR079197A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| AR105616A1 (es) | Proteínas de fusión | |
| BR112018073511A2 (pt) | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos | |
| AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
| AR081975A1 (es) | Analogos de glucagon | |
| AR088161A1 (es) | Analogos de glucagon | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| MX2011013183A (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. | |
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| AR098065A1 (es) | Análogos de glucagón acilados | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |